Applications of SARS-CoV-2 Serological Assays for Patient Management in an Acute Care Setting
Duration: 60 minutes
Sep 7, 2020
In this recorded webinar, Dr. Karen Roush speaks about how a COVID-19 Total antibody test I being used at a large metropolitan health system to help manage patient care.
Hear about an algorithm that was developed for patient assessment prior to elective surgeries and the role antibody tests have together with molecular tests in an acute care setting.
About our Speaker:
About our Speaker:
Karen S. Roush, MD, MBA
Vice Chairman Department of Pathology, Methodist Health System
Dallas, TX
Dr. Roush also serves at the Medical Director for Transfusion Services for Methodist Health System as well as the Medical Director of Pathology, at the Methodist Hospital Surgery in Addison, Texas.
She also serve as a member of several hospital committees including the Quality Committee for Methodist Dallas Medical Center, Medical Executive Committee for Methodist Hospital for Surgery and Methodist McKinney Hospital, Chair of the Pharmacy and Therapeutics Committee at Methodist Medical Center, and chair of the Quality Performance Committee for Methodist Hospital Surgery.
She is the author of several books and book chapters on the topic of blood banking and transfusion medicine in addition to articles that have been published in peer-reviewed journals.
Dr. Roush also serves at the Medical Director for Transfusion Services for Methodist Health System as well as the Medical Director of Pathology, at the Methodist Hospital Surgery in Addison, Texas.
She also serve as a member of several hospital committees including the Quality Committee for Methodist Dallas Medical Center, Medical Executive Committee for Methodist Hospital for Surgery and Methodist McKinney Hospital, Chair of the Pharmacy and Therapeutics Committee at Methodist Medical Center, and chair of the Quality Performance Committee for Methodist Hospital Surgery.
She is the author of several books and book chapters on the topic of blood banking and transfusion medicine in addition to articles that have been published in peer-reviewed journals.
Disclaimer:
The information discussed also represents the best available information available at the time of the live presentation and audiences viewing replays of this presentation should always independently assess any government announcements, regulation or industry guideline updates relevant to the topic.
The audience is reminded to consult all instructions for use and current intended use for products referenced during the presentation.The VITROS Anti-SARS-CoV-2 Total and IgG tests have not been FDA cleared or approved. They have been authorized by the FDA under an emergency use authorization and testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate or high complexity tests.
The VITROS Antibody tests have been authorized only for the detection of either Total or IgG antibodies from SARS-CoV-2, not for any other viruses or pathogens, and results should not be used as the sole basis for diagnosis.These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
